An open-lable, single-center, phase I study to assess safety, tolerance, pharmacokinetics and efficacy of Fluorapacin Injection in various patients with solid tumor, mainly in phase IV lung cancer.
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Fluorapacin (Primary)
- Indications Lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors ACE BioSciences
- 26 May 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01361529), additional identifier added.
- 07 Nov 2009 New trial record